Exelixis EXEL Business Segments — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's business segments — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's business segments — total revenues?
- Exelixis (EXEL) reported business segments — total revenues of $610.81M in Q1 2026.
- How has Exelixis's business segments — total revenues changed year-over-year?
- Exelixis's business segments — total revenues increased by 10.0% year-over-year, from $555.45M to $610.81M.
- What is the long-term trend for Exelixis's business segments — total revenues?
- Over 3 years (2022 to 2025), Exelixis's business segments — total revenues has grown at a 12.9% compound annual growth rate (CAGR), from $1.61B to $2.32B.
- What does business segments — total revenues mean?
- The total amount of money brought in by the company's main business segment from sales and licensing.
- How do you interpret business segments — total revenues?
- An increase indicates successful commercial execution and market penetration, while a decrease may signal competitive pressure or patent expirations.
- How does business segments — total revenues compare across companies?
- Standard revenue metric across all biopharmaceutical companies, comparable to net product sales.